AI Article Synopsis

  • T cell receptor (TCR) signaling is crucial for T cell development and function, but studying specific TCR responses has been challenging due to the variety of TCRs.
  • A new method using retroviral transduction of bone marrow allows for the faster creation of retrogenic mice, which can be developed in about six weeks instead of six months.
  • This approach provides a flexible alternative for studying TCRs in various genetic backgrounds, facilitating better research on T cell responses.

Article Abstract

T cell receptor (TCR) signaling is essential in the development and differentiation of T cells in the thymus and periphery, respectively. The vast array of TCRs proves studying a specific antigenic response difficult. Therefore, TCR transgenic mice were made to study positive and negative selection in the thymus as well as peripheral T cell activation, proliferation and tolerance. However, relatively few TCR transgenic mice have been generated specific to any given antigen. Thus, studies involving TCRs of varying affinities for the same antigenic peptide have been lacking. The generation of a new TCR transgenic line can take six or more months. Additionally, any specific backcrosses can take an additional six months. In order to allow faster generation and screening of multiple TCRs, a protocol for retroviral transduction of bone marrow was established with stoichiometric expression of the TCRα and TCRβ chains and the generation of retrogenic mice. Each retrogenic mouse is essentially a founder, virtually negating a founder effect, while the length of time to generate a TCR retrogenic is cut from six months to approximately six weeks. Here we present a rapid and flexible alternative to TCR transgenic mice that can be expressed on any chosen background with any particular TCR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993443PMC
http://dx.doi.org/10.3791/54196DOI Listing

Publication Analysis

Top Keywords

tcr transgenic
16
transgenic mice
12
retroviral transduction
8
transduction bone
8
bone marrow
8
retrogenic mice
8
tcr
7
mice
5
marrow progenitor
4
progenitor cells
4

Similar Publications

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

Front Immunol

December 2024

Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine, Technical University of Munich, Munich, Germany.

Introduction: Pediatric sarcomas, including osteosarcoma (OS), Ewing sarcoma (EwS) and rhabdomyosarcoma (RMS) carry low somatic mutational burden and low MHC-I expression, posing a challenge for T cell therapies. Our previous study showed that mediators of monocyte maturation sensitized the EwS cell line A673 to lysis by HLA-A*02:01/CHM1-specific allorestricted T cell receptor (TCR) transgenic CD8 T cells (CHM1 CD8 T cells).

Methods: In this study, we tested a panel of monocyte maturation cytokines for their ability to upregulate immunogenic cell surface markers on OS, EwS and RMS cell lines, using flow cytometry.

View Article and Find Full Text PDF

CD8+ T-cell immunity, mediated through interactions between human leukocyte antigen (HLA) and the T-cell receptor (TCR), plays a pivotal role in conferring immune memory and protection against viral infections. The emergence of SARS-CoV-2 variants presents a significant challenge to the existing population immunity. While numerous SARS-CoV-2 mutations have been associated with immune evasion from CD8+ T cells, the molecular effects of most mutations on epitope-specific TCR recognition remain largely unexplored, particularly for epitope-specific repertoires characterized by common TCRs.

View Article and Find Full Text PDF

High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells.

Nat Commun

December 2024

Technical University of Munich, School of Medicine and Health, III Medical Department, TUM University Hospital, Ismaninger Str. 22, 81675, Munich, Germany.

Neoantigen-specific T cell receptors (neoTCRs) promise safe, personalized anti-tumor immunotherapy. However, detailed assessment of neoTCR-characteristics affecting therapeutic efficacy is mostly missing. Previously, we identified diverse neoTCRs restricted to different neoantigens in a melanoma patient.

View Article and Find Full Text PDF

The T-cell receptor sequences expressed on cells recognizing a specific peptide in the context of a given MHC molecule can be explored for common features that might explain their antigen specificity. However, despite the development of numerous experimental and bioinformatic strategies, the specificity problem remains unresolved. To address the need for additional experimental paradigms, we report here on an in vivo experimental strategy designed to artificially diversify a transgenic TCR by CRISPR/Cas9-mediated mutagenesis of Tcra and Tcrb chain genes.

View Article and Find Full Text PDF
Article Synopsis
  • Glypican-3 (GPC3) is a potential target for T-cell therapy in hepatocellular carcinoma (HCC), but current CAR T-cell approaches face issues like low persistence and GPC3 shedding.
  • Researchers immunized HLA-A2 transgenic mice to find GPC3-specific T-cell receptors (TCRs) and engineered human T cells (TCR-Ts) that effectively recognize GPC3-positive HCC cells.
  • TCR-B-T cells showed superior effectiveness compared to traditional CAR T-cells, and combining CAR-T and TCR-B-T cells may enhance therapeutic results in treating HCC.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!